Arbutus Biopharma (ABUS) Prepaid Assets (2010 - 2026)

Arbutus Biopharma (ABUS) has reported Prepaid Assets for 17 consecutive years, with $1.7 million the latest figure, recorded in Q1 2026.

• Quarterly Prepaid Assets fell 40.66% year-over-year to $1.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $1.7 million (down 40.66% YoY) and the FY2025 annual result came in at $1.5 million, down 32.66% from the prior year.
• Prepaid Assets advanced to $1.7 million in Q1 2026 per ABUS's latest filing, from $1.5 million in the prior quarter.
• Over the last five years, Prepaid Assets for ABUS reached as high as $5.9 million in Q1 2022 and fell as low as $1.5 million in Q4 2025.
• A 5-year average of $3.7 million and a median of $3.7 million in 2023 frame the typical range for Prepaid Assets.
• Annual changes were most pronounced in 2022 — Prepaid Assets surged 48.38% — and 2024, when it sank 46.23%.
• Year by year, Prepaid Assets stood at $2.9 million in 2022, then soared by 47.81% to $4.2 million in 2023, then sank by 46.23% to $2.3 million in 2024, then tumbled by 32.66% to $1.5 million in 2025, then climbed by 12.61% to $1.7 million in 2026.
• According to Business Quant data, Prepaid Assets over the past three periods registered $1.7 million, $1.5 million, and $2.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.